安进股价上涨,因其自身免疫疾病药物达到晚期临床试验目标

路透中文
Sep 22
BUZZ-<a href="https://laohu8.com/S/AMGN">安进</a>股价上涨,因其自身免疫疾病药物达到晚期临床试验目标

9月22日 - ** 制药公司安进(Amgen) AMGN.O 的股价上涨2.4%,至402.69美元

** 该公司表示,其用于治疗舍格伦综合征的实验性药物达佐达利贝普(dazodalibep)在后期临床试验中达到了降低疾病活动度的主要目标 (link)

** 舍格伦综合征是一种自身免疫性疾病,会导致眼睛、口腔及身体其他部位干燥,并伴有疲劳和慢性疼痛

** 该药物在第48周时显示出具有统计学意义且临床意义显著的改善;大多数副作用为轻度至中度

** 该公司计划在即将举行的医学会议上公布详细结果

** 计入本次交易,AMGN今年以来累计上涨23.1%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10